Hyaluronic acid as a predictor of exacerbation of occupational chronic obstructive pulmonary disease

The frequency of exacerbations of chronic obstructive pulmonary disease (COPD) is one of the main factors determining the outcome. The search for biomarkers which reflect the risk of exacerbations is one of the urgent scientific and practical objectives. Aim. The study aimed to analyze the relationship between the serum concentration of hyaluronic acid (HA) and the frequency of exacerbations of occupational COPD caused by exposure to silica dust and to substantiate the use of HA as a predictor of exacerbations of COPD. Methods. 78 individuals with a diagnosis of occupational COPD were examined. Respiratory function was assessed based on forced vital capacity of the lungs (FVC, %), the forced expiratory volume in 1 second (FEV₁, %) and the calculated ratio of these parameters (FEV₁/FVC, %), i.e., modified Tiffno index. The serum concentration of hyaluronic acid (ng/ml) was determined in all individuals using solid-phase enzyme-linked immunosorbent assay (ELISA). The absolute blood level of eosinophils (cell/μl) was determined by a unified method of morphological study of hemocytes with white blood cell differential count. Results. Serum HA concentration in patients with occupational COPD with frequent exacerbations was 25% higher than in the patients with rare exacerbations (the difference was statistically significant; р = 0,004). The analysis of the obtained data showed that the most significant moderate correlation was found between the level of HA and the frequency of COPD exacerbations (direct relationship, r = 0.32; p < 0.05), and FEV₁ and the frequency of COPD exacerbations (feedback, r = -0.32;p < 0.05). A weak relationship was found between the relative number of eosinophils and the frequency of COPD exacerbations (direct relationship, r = 0.2; p < 0.05). Weak correlations were also found between the level of HA and FEV1 (feedback, r = -0.23; p < 0.05), between the level of HA and the relative number of eosinophils (direct relationship, r = 0.18; p < 0.05). Conclusion. Quantitative analysis of serum HA in patients with occupational COPD can be used in clinical practice as a biochemical marker for assessing the risk of exacerbations and progression of bronchopulmonary pathology.

1. Fedotov V.D., Shoniya M.L., Belous'ko N.I. [Clinical and prognostic aspects of the relationship of chronic obstructive pulmonary disease of occupational etiology and chronic non-obstructive bronchitis]. Meditsina truda i promyshlennaya ekologiya. 2020; 60 (1): 53-58. DOI: 10.31089/1026-9428-2020-60-1-53-58 (in Russian).

2. Shaw J.G., Vaughan А., Dent A.G. et al. Biomarkers of progression of chronic obstructive pulmonary disease (COPD). J. Thorac. Dis. 2014; 6 (11): 1532-1547. DOI: 10.3978/j.issn.2072-1439.2014.11.33.

3. Hillas G., Perlikos F., Tzanakis N. Acute exacerbation of COPD: is it the “stroke of the lungs”? Int. J. Chron. Obstruct. Pulmon. Dis. 2016; 11 (1): 1579-1586. DOI: 10.2147/COPD.S106160.

4. Barnes P.J., Chowdhury B., Kharitonov S.A. et al. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2006; 174 (1): 6-14. DOI: 10.1164/rccm.200510-1659PP.

5. Agusti А., Edwards L.D., Rennard S.I. et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012; 7 (5): e37483. DOI: 10.1371/journal.pone.0037483.

6. Ritchie A.I., Wedzicha J.A. Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations. Clin. Chest Med. 2020; 41 (3): 421-438. DOI: 10.1016/j.ccm.2020.06.007.

7. Chilosi M., Poletti V., Rossi A. The pathogenesis of COPD and IPF: distinct horns of the same devil? Respir. Res. 2012; 13 (1): 3. DOI: 10.1186/1465-9921-13-3.

8. R0nnow S.R., Bulow S.J.M., Langholm L.L. et al. Type IV collagen turnover is predictive of mortality in COPD: a comparison to fibrinogen in a prospective analysis of the ECLIPSE cohort. Respir Res. 2019; 20 (1): 63. DOI: 10.1186/s12931-019-1026-x.

9. Singh D., Wedzicha J.A., Siddiqui S., de la Hoz A. Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials. Respir. Res. 2020; 21 (1): 240. DOI: 10.1186/s12931-020-01482-1.

10. Ormiston M.L., Slaughter G.R., Deng Y. et al. The enzymatic degradation of hyaluronan is associated with disease progression in experimental pulmonary hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 2010; 298 (2): 148-157. DOI: 10.1152/ajplung.00097.2009.

11. Eurlings I.M., Dentener M.A., Mercken E.M. et al. A comparative study of matrix remodeling in chronic models for COPD; mechanistic insights into the role of TNF-а. Am. J. Physiol. Lung Cell. Mol. Physiol. 2014; 307 (7): L557-565. DOI: 10.1152/ajplung.00116.2014.

12. Fedotov V.D., Blinova T.V. Strakhova L.A. et al. [Hyaluronic acid as a marker for remodeling of bronchopulmonary system in patients with occupational pulmonary pathology]. Pul'monologiya. 2019; 29 (6): 679-684. DOI: 10.18093/0869-0189-2019-29-6-679-684 (in Russian).

13. Chuchalin A.G., Avdeev S.N., Aisanov Z.R. [Russian respiratory society. Federal guidelines on diagnosis and treatment of chronic obstructive pulmonary disease]. Pul'monologiya. 2018; (3): 15-54. DOI: 10.18093/0869-0189-2014-0-3-15-54 (in Russian).

14. Izmerov N.F., Chuchalin A.G., eds. [Occupational respiratory diseases: guidelines]. Moscow: GEOTAR-Media; 2015 (in Russian).

15. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2021 Report. Available at: https://goldcopd.org/wp-content/uploads/2020/11/gold-report-2021-v1.1-25Nov20_WMV.pdf [Accessed: June 10, 2021].

16. Men'shikov V.V., ed. [Clinical laboratory techniques: a reference guide]. Moscow: Labora. 2009. Vol. 1 (in Russian).

17. Organov R.G., ed. [National guidelines for the diagnosis and significance of metabolic syndrome]. 3rd edn. Moscow: Solitsea-Poligra; 2010 (in Russian).

18. Garantziotis S., Brezina M., Castelnuovo P. et al. The role of hyaluronan in the pathobiology and treatment of respiratory disease. J. Physiol. Lung Cell. Mol. Physiol. 2016; 310 (9): L785-795. DOI: 10.1152/ajplung.00168.2015.

19. Lipson D.A., Barnhart F., Brealey N. et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N. Engl. J. Med. 2018; 378 (18): 1671-1680. DOI: 10.1056/NEJMoa1713901.